Coronary Artery Blockage Treatment: Meds, Stents, Bypass & Emerging Options

Managing Coronary Artery Disease (CAD): A Tiered Approach

Coronary artery blockage (atherosclerotic plaque narrowing luminal diameter) is treated based on symptom burden, ischemia extent, anatomy, left ventricular function, comorbidities, and patient preference.

1. Guideline-Directed Medical Therapy (GDMT) – Foundation for All

Class	Agents	Target / Benefit
Antiplatelet	Aspirin 81 mg daily ± P2Y12 inhibitor (clopidogrel, ticagrelor) if ACS/stent	Prevent thrombosis
Statin (high-intensity)	Atorvastatin 40–80 mg / Rosuvastatin 20–40 mg	LDL <55 mg/dL (very high risk) or <70; plaque stabilization
Beta-blocker	Metoprolol succinate, carvedilol, bisoprolol	Reduce O₂ demand, post-MI mortality benefit
ACEi / ARB	Lisinopril, ramipril / losartan, valsartan	LV dysfunction, HTN, DM, CKD
SGLT2 inhibitor	Empagliflozin, dapagliflozin	HF, DM, CKD – CV/death reduction
Anti-anginal	Ranolazine, nitrates, ivabradine (if HR>70 on max BB)	Symptom control

2. Lifestyle Modification (Class I)

• Mediterranean/plant-predominant diet.
• 150 min moderate aerobic + resistance 2×/week.
• Smoking cessation (varenicline, bupropion, NRT + counseling).
• Weight management (BMI 20–25, waist <94 cm M / <80 cm F).
• Stress reduction (TM, MBSR, cardiac rehab).
• Blood pressure <130/80; diabetes HbA1c <7%.

3. Revascularization: PCI vs. CABG

Percutaneous Coronary Intervention (PCI / Angioplasty + Stent)

• Indications: ACS (STEMI/NSTEMI), stable angina refractory to GDMT, ischemia on testing (FFR ≤0.80, iFR ≤0.89).
• Stents: Drug-eluting (DES) – everolimus, zotarolimus, sirolimus; bioresorbable scaffolds (limited use).
• Physiology-guided: FFR/iFR, IVUS/OCT optimization.
• Complex PCI: CTO, bifurcation, calcified (rotablation, IVL), left main (low SYNTAX).

Coronary Artery Bypass Grafting (CABG)

• Indications: Left main disease, multivessel disease (esp. diabetes, SYNTAX >22), proximal LAD + other vessels, failed PCI, reduced LVEF with viable myocardium.
• Conduits: LIMA to LAD (gold standard), radial artery, saphenous vein grafts.
• Off-pump vs. on-pump: Surgeon preference; similar outcomes in experienced hands.
• Hybrid: LIMA-LAD + PCI to non-LAD.

Decision Framework (Heart Team)

Anatomy / Clinical	Preferred
Left main, low SYNTAX (≤22)	PCI or CABG (shared decision)
Left main, high SYNTAX (>22)	CABG
3-vessel, diabetes	CABG
3-vessel, no diabetes, low SYNTAX	PCI or CABG
Proximal LAD + 1-vessel	CABG (LIMA-LAD benefit)
1-2 vessel, no prox LAD	PCI
STEMI	Primary PCI

4. Advanced / Niche Therapies

• Atherectomy: Rotational, orbital, laser, directional – for heavily calcified lesions pre-stent (IVL now preferred).
• Intravascular Lithotripsy (IVL): Shockwave calcium modification – game-changer for calcification.
• Bioresorbable scaffolds: Limited to specific anatomies; late thrombosis risk.
• ECMO / Impella / IABP: Mechanical circulatory support for cardiogenic shock / high-risk PCI.
• Gene / cell therapy, angiogenesis: Experimental (refractory angina).

5. Follow-Up & Secondary Prevention

• Cardiac rehab (Class I) – 36 sessions; reduces mortality 25–30%.
• Annual stress testing only if symptoms change.
• Lifelong GDMT adherence.
• Influenza, pneumococcal, COVID vaccines.

Revascularization treats symptoms and (in select anatomy) improves survival—but medical therapy treats the disease. The heart team ensures the right procedure for the right patient at the right time.